

# The Growing Toolbox for Atopic Dermatitis: Biologics and JAK Inhibitors

Brett King, MD, PhD and Chris Bunick, MD, PhD

Yale School of Medicine, Department of Dermatology

# Biologics and JAK inhibitors for AD

## Dupilumab<sup>1</sup>

- IL-4/IL-13 inhibitor
- Indicated for ages ≥6 months

## Tralokinumab<sup>2</sup>

- IL-13 inhibitor
- Indicated for ages ≥12 years

## Abrocitinib<sup>1</sup>

- JAK1 inhibitor
- Indicated for ages ≥12 years

## Upadacitinib<sup>2</sup>

- JAK1/2 inhibitor
- Indicated for ages ≥12 years

### Benefits

- Highly or modestly effective<sup>3,4</sup>
- Injectable<sup>1,2</sup>
- Daily dosing not required

### Limitations

- Injectable<sup>1,2</sup>

### Benefits

- Highly effective with rapid suppression of itch<sup>3,4</sup>
- Oral<sup>1,2</sup>
- Potential for episodic use<sup>5</sup>

### Limitations

- Boxed Warning<sup>1,2</sup>

**References:** 1. Dupilumab prescribing information. FDA website. Revised October 2022. Accessed February 27, 2023. 2. Tralokinumab prescribing information. FDA website. Revised December 2021. Accessed February 27, 2023. 3. Thaçi D et al. *J Dermatol Sci*. 2019;94:266-275. 4. Wollenberg A et al. *Br J Dermatol*. 2021;184:437-449.


**References:** 1. Abrocitinib prescribing information. FDA website. Revised January 2022. Accessed February 27, 2023. 2. Upadacitinib prescribing information. FDA website. Revised October 2022. Accessed February 27, 2023. 3. Simpson EL et al. *Lancet*. 2020;396:255-266. 4. Blauvelt A et al. *JAMA Dermatol*. 2021;157:1047-1055. 5. Blauvelt A et al. *J Am Acad Dermatol*. 2022;86:104-112.

# Comparing Efficacy of JAK Inhibitors and Dupilumab

# Upadacitinib vs Dupilumab: Heads Up

- 24-week trial of upadacitinib 30 mg QD vs. dupilumab 300 mg Q2weeks\* in adults

**EASI 75 through Week 24 (NRI-C)**




\*P<0.05 vs dupilumab (nominal at Week 1)

\* After dupilumab 600 mg loading dose

NRS = Numerical Rating Scale (0=no itch...10=worst imaginable itch)

**D Worst pruritus NRS**




Blauvelt A, et al. JAMA Dermatol 2021;157:1047-55.


# Abrocitinib vs Dupilumab: JADE DARE

- 26-week trial of abrocitinib 200 mg vs. dupilumab 300 mg Q2weeks

**EASI 90 through Week 26 (NRI<sup>a</sup>)**



**PP NRS through Week 26 (NRI<sup>a</sup>)**




IGA = Investigator Global Assessment (0=clear, 1=almost clear...); PP NRS = Peak Pruritus Numerical Rating Scale (0=no itch...10=worst imaginable itch)


\*P<0.001 abrocitinib vs dupilumab; <sup>a</sup>Patients discontinuing treatment were imputed with NRI, for intermittent missing data no imputation was used

# JAK Inhibitor Treatment of Dupilumab Failures

# Abrocitinib in patients not achieving responses to dupilumab: JADE EXTEND



## Outcomes with abrocitinib at Week 12 of JADE EXTEND among nonresponders<sup>a</sup> to 16 weeks' dupilumab in JADE COMPARE



IGA = Investigator Global Assessment (0=clear, 1=almost clear...); NRS = Numerical Rating Scale (0=no itchy skin, 1=almost no itchy skin, 2=some itchy skin, 3=moderate itchy skin, 4=severe itchy skin)  
 Statistical methodology, including imputation methods, not included in poster  
 Bieber T, et al. N Engl J Med 2021;384:1101–12.  
 Shi V, et al. AAD VMX 2021, P27590. Sponsored by Pfizer Inc.

<sup>a</sup>Nonresponders = patients receiving dupilumab who did not achieve the responses displayed at Week 16 of JADE COMPARE

# Putting it all together...

With an expanding toolbox, we should strive for

- IGA 0/1
- Pruritus NRS 0/1

If at first you don't succeed, try, try again!



If at first you don't achieve IGA 0/1 AND PRURITUS NRS 0/1, try, try another treatment!